Brief: BioArctic's Leqembi Approved For Treatment Of Early Alzheimer's Disease In Australia
24/09/2025 07:42
Sept 24 (Reuters) - BioArctic AB BIOAb.ST: LEQEMBI APPROVED FOR THE TREATMENT OF EARLY ALZHEIMER'S DISEASE IN AUSTRALIA Source text: ID:nWkrbt5HPK Further company coverage: [BIOAb.ST] (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on BioArctic AB
See all newsBrief: BioArctic And Lilly Sign Research, Collaboration Agreement
Brief: Bioarctic AB Declares Dividend Of Sek 2 Per Share With 1 June 2026 Record Date
Brief: Bioarctic Partner Eisai Presents Leqembi Sales Simulation
Sweden's BioArctic Q1 revenue drops sharply despite higher Leqembi royalties
Brief: BioArctic Q1 Operating Profit SEK 210.8 Million